Clinical Trial News and Research RSS Feed - Clinical Trial News and Research

Columbia Laboratories reports 44% year-over-year decrease in CRINONE product revenues

Columbia Laboratories, Inc. today announced financial results for the three and six-month periods ended June 30, 2014. [More]

Genae establishes offices in London to provide high quality research services on global scale

genae, a global Contract Research Organization (CRO) and services provider for the medical industries, announced today the incorporation of genae UK in London. [More]
Researchers to develop global database on situation and evolution of Chagas disease

Researchers to develop global database on situation and evolution of Chagas disease

The Centre for Development Cooperation (CCD) and several research groups of the Universitat Polit├Ęcnica de Catalunya (UPC) are working together with the World Health Organization (WHO) to develop a global database on the situation and evolution of Chagas disease. [More]
Statin therapy may speed up wound healing following cardiac surgery

Statin therapy may speed up wound healing following cardiac surgery

Statin therapy may help to improve wound healing in patients following cardiac surgery and reduce overall recovery time, especially in patients who are prone to healing complications, according to a review article in the August 2014 issue of The Annals of Thoracic Surgery. [More]
Naltrexone may be effective in diminishing ICD symptoms in PD patients, study finds

Naltrexone may be effective in diminishing ICD symptoms in PD patients, study finds

Up to 20 percent of Parkinson's disease (PD) patients and their families may confront a common but largely unrecognized challenge: the occurrence of impulse control disorders (ICDs) such as compulsive gambling, sexual behavior, eating, or spending. [More]
UK researcher working to develop online tool to help patients navigate lung cancer screening decision

UK researcher working to develop online tool to help patients navigate lung cancer screening decision

The phrase "we caught it early" is possibly the best news a patient can hear in the midst of a cancer diagnosis. Combating cancer in its earliest stages, when the disease is localized to a certain part of the body, gives patients the best chances of survival. [More]
CardioNova initiates Phase 1b clinical trial with AtheroNova's AHRO-001

CardioNova initiates Phase 1b clinical trial with AtheroNova's AHRO-001

AtheroNova Inc., a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announces that its partner, CardioNova, has accomplished first dosing of subjects for its Phase 1b clinical trial with AtheroNova's lead compound, AHRO-001. [More]
Researchers establish new strategy to help surgeons see entire tumor in patient

Researchers establish new strategy to help surgeons see entire tumor in patient

The best way to cure most cases of cancer is to surgically remove the tumor. The Achilles heel of this approach, however, is that the surgeon may fail to extract the entire tumor, leading to a local recurrence. [More]
Diet rich in soy may help feminine hearts, but timing matters

Diet rich in soy may help feminine hearts, but timing matters

A diet rich in soy may help feminine hearts, but timing matters, finds a new study published online today in Menopause, the journal of The North American Menopause Society. [More]
EMD Serono begins MSB0010718C Phase II study in mMCC patients

EMD Serono begins MSB0010718C Phase II study in mMCC patients

EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, today announced the initiation of an international Phase II study designed to assess the efficacy and safety of MSB0010718C, an investigational fully human IgG1 monoclonal antibody that binds to programmed death-ligand 1 (PD-L1). [More]
FDA approves use of Imbruvica to treat patients with chronic lymphocytic leukemia

FDA approves use of Imbruvica to treat patients with chronic lymphocytic leukemia

The U.S. Food and Drug Administration today expanded the approved use of Imbruvica (ibrutinib) to treat patients with chronic lymphocytic leukemia (CLL) who carry a deletion in chromosome 17 (17p deletion), which is associated with poor responses to standard treatment for CLL. Imbruvica received a breakthrough therapy designation for this use. [More]
University of Bradford researchers devise simple blood test to diagnose cancer

University of Bradford researchers devise simple blood test to diagnose cancer

Researchers from the University of Bradford, UK, have devised a simple blood test that can be used to diagnose whether people have cancer or not. [More]
Cardioxyl reports positive results from CXL-1427 Phase I trial for treatment of ADHF

Cardioxyl reports positive results from CXL-1427 Phase I trial for treatment of ADHF

Cardioxyl Pharmaceuticals, Inc. announced today the positive results of a clinical trial demonstrating that CXL-1427, a novel potential treatment for acute decompensated heart failure (ADHF), was well tolerated in healthy volunteers. [More]
Adopting a comprehensive and integrative healing strategy for cancer

Adopting a comprehensive and integrative healing strategy for cancer

The cancer drugs, radiation therapy and cancer surgery available today help millions of people survive their cancer. [More]
XPro1595 drug can protect vulnerable neurons, reduce motor deficits in Parkinson's model

XPro1595 drug can protect vulnerable neurons, reduce motor deficits in Parkinson's model

An experimental anti-inflammatory drug can protect vulnerable neurons and reduce motor deficits in a rat model of Parkinson's disease, researchers at Emory University School of Medicine have shown. [More]
Researchers demonstrate novel approach in cervical cancer prevention

Researchers demonstrate novel approach in cervical cancer prevention

A study published online in the International Journal of Cancer earlier this month describes a novel approach to preventing cervical cancer based on findings showing successful reduction in the risk of cervical cancer after removal of a discrete population of cells in the cervix. [More]
FDA issues Complete Response Letter for AcelRx's Zalviso NDA

FDA issues Complete Response Letter for AcelRx's Zalviso NDA

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the Company's new drug application (NDA) for Zalviso (sufentanil sublingual tablet system). [More]
Galmed reports net loss of $3.9 million for six months ended June 30, 2014

Galmed reports net loss of $3.9 million for six months ended June 30, 2014

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones, today announced financial results for the period ended June 30, 2014. [More]
Biogen Idec receives marketing authorization from EC for multiple sclerosis drug

Biogen Idec receives marketing authorization from EC for multiple sclerosis drug

Today Biogen Idec announced that the European Commission (EC) has granted marketing authorization for PLEGRIDY (peginterferon beta-1a) as a treatment for adults with relapsing-remitting multiple sclerosis (RRMS), the most common form of multiple sclerosis (MS). [More]
New treatment fights respiratory syncytial virus in children

New treatment fights respiratory syncytial virus in children

Researchers at Le Bonheur Children's Hospital and the University of Tennessee Health Science Center announced results of a clinical trial of a new drug shown to safely reduce the viral load and clinical illness of healthy adult volunteers intranasally infected with respiratory syncytial virus (RSV). [More]